Penn Medicine has announced a new Translational Center of Excellence in the Abramson Cancer Center, focused on glioblastoma multiforme. The team will investigate new immune therapies for glioblastoma and, in particular, design and test new chimeric antigen receptor (CAR) T-cell therapies.
Donald M. O’Rourke, MD
“Penn Medicine is at the cutting edge of research and clinical care for patients with glioblastoma, and our [Translational Center] will help accelerate this mission-critical work,” said Donald M. O’Rourke, MD, John Templeton, Jr, MD, Associate Professor in Neurosurgery in the Perelman School of Medicine at the University of Pennsylvania, who will lead the Translational Center (a partnership of the Abramson Cancer Center and the Department of Neurosurgery). ■